L1CA34 Stock Overview
Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
Laboratory Corporation of America Holdings Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$262.60 |
| 52 Week High | US$292.29 |
| 52 Week Low | US$244.57 |
| Beta | 0.99 |
| 1 Month Change | -2.74% |
| 3 Month Change | -3.54% |
| 1 Year Change | -7.91% |
| 3 Year Change | -27.36% |
| 5 Year Change | n/a |
| Change since IPO | 40.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| L1CA34 | BR Healthcare | BR Market | |
|---|---|---|---|
| 7D | -1.4% | -3.2% | 0.1% |
| 1Y | -7.9% | 4.4% | 14.3% |
Return vs Industry: L1CA34 underperformed the BR Healthcare industry which returned 6.3% over the past year.
Return vs Market: L1CA34 underperformed the BR Market which returned 15.7% over the past year.
Price Volatility
| L1CA34 volatility | |
|---|---|
| L1CA34 Average Weekly Movement | 2.3% |
| Healthcare Industry Average Movement | 5.9% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in BR Market | 8.2% |
| 10% least volatile stocks in BR Market | 2.2% |
Stable Share Price: L1CA34 has not had significant price volatility in the past 3 months.
Volatility Over Time: L1CA34's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 61,975 | Adam Schechter | www.labcorp.com |
Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS). The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.
Laboratory Corporation of America Holdings Fundamentals Summary
| L1CA34 fundamental statistics | |
|---|---|
| Market cap | R$88.51b |
| Earnings (TTM) | R$1.93b |
| Revenue (TTM) | R$61.76b |
46.0x
P/E Ratio1.4x
P/S RatioIs L1CA34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| L1CA34 income statement (TTM) | |
|---|---|
| Revenue | US$12.16b |
| Cost of Revenue | US$8.80b |
| Gross Profit | US$3.36b |
| Other Expenses | US$2.99b |
| Earnings | US$379.20m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 25, 2024
| Earnings per share (EPS) | 4.51 |
| Gross Margin | 27.67% |
| Net Profit Margin | 3.12% |
| Debt/Equity Ratio | 64.1% |
How did L1CA34 perform over the long term?
See historical performance and comparison